Neal D. Shore, MD

Neal D. Shore, MD

Carolina Urologic Research Center and Atlantic Urology Clinics, LLC

Myrtle Beach, SC

Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, and is Immediate Past President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE (Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 200 peer-reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high-impact scientific journals. A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.

Articles by Neal D. Shore, MD

Preserving Independent Urology: LUGPA’s First Decade

Neal D. Shore, MD and E. David Crawford, MD, discuss Dr. Shore’s recent MedReview article (excerpted and linked below) on the ways in which the Large Urology Group Practice Association, or LUGPA, has advocated on behalf of community urology physicians and patients over the last ten years. Dr. Shore discusses how the organization has fought for legislative change to improve patient access to physicians of their choice, worked to ensure the availability of the latest in imaging and diagnostic technology for community urologists, and, in the face of increased consolidation of the healthcare industry, promoted value-based healthcare above volume-based healthcare, concluding in the article that:

“Eleven years after LUGPA’s inception, its passion and commitment to protecting and preserving the independent practice of urology remain stronger than ever. Without LUGPA, there would be far fewer opportunities for independent urology practices, fair-balanced education, networking, or external benchmarking than we have today. LUGPA groups have been able to integrate essential urologic services at a lower cost than their hospital competitors. Many of our member practices have become urologic centers of excellence with subspecialty lines of service and innovative, cost-effective pathways that optimize patient outcomes.

“Innovation springs from independence, not bureaucracy. Independent practitioners have the freedom and flexibility to share decision-making with their patients and to rapidly implement, test, and adapt new diagnostics, therapeutics, and pathways. Backed by a robust organization such as LUGPA, independent urologists can implement innovative approaches that significantly improve the health of their patients and the sustainability of their practices. Such nimbleness is especially crucial given the current rapid pace of change in urology. Aligning the interests of patients, providers, and payers by promoting value-based care at independent, integrated physician practices is LUGPA’s ongoing mission; our rallying cry should be to continue that mission in an open, transparent, and inclusive fashion.” (Used with permission from MedReviews / Reviews in Urology, which holds the copyright to the original article.)

Read More

Phase III HERO Trial: Once-Daily, Oral Relugolix Results in 96.7% Testosterone Suppression in Men with Advanced Prostate Cancer

Neal D. Shore, MD, a HERO Program Steering Committee Member, discusses the results of his group’s global, prospective, randomized, phase III trial. This trial evaluated once-daily, oral relugolix, a gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of advanced prostate cancer against a control arm of patients receiving 3-month leuprolide injections. The primary endpoint of sustained testosterone suppression for 48 weeks was met, as well as 6 key secondary endpoints, and the reported major adverse cardiovascular events favored relugolix over the control arm.

Read More

The Gold Standard for Bladder Cancer Detection

Neal D. Shore, MD, discusses the benefits of using blue light cystoscopy (BLC) in adjunct with white light cystoscopy (WLC) in the diagnosis and treatment of bladder cancers. He then reviews the body of evidence evaluating the accuracy of BLC in detecting significant tumors and briefly compares BLC and narrow band imaging.

Read More

Navigating the M0 Space- Results of RADAR III

Neal D. Shore, MD, reviews the recently-published guidelines focused on next generation imaging for early detection of disease progression in M0 prostate cancer in the Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence III (RADAR III). He also reviews the goals and conclusions from RADAR I and II.

Read More

Join the GRU Community

- Why Join? -